

TABLE OF CONTENTS

S. No.	Title	Page No.
CHAPTER 1	INTRODUCTION	1-26
1.1.	General	1-2
1.2.	Breast cancer	2-3
1.3.	MAPK pathway	3-6
1.4.	Targeting different members of MAPK pathway	6
1.4.1.	KRAS inhibitors	6-8
1.4.2.	Problems associated with KRAS inhibitors	8
1.4.3.	B-RAF inhibitors	8-10
1.4.4.	Problems associated with B-RAF inhibitors	10-11
1.4.5.	MEK inhibitors	11-13
1.4.6.	Problems associated with MEK inhibitors	13
1.5.	Putative way to bypass resistance against MAPK pathway	13-16
1.6.	Substituted pyrimidines as a source of diverse pharmacophore	16-18
1.7.	Computer-aided drug design (CADD)	18
1.7.1.	Scaffold hopping	19-20
1.7.2.	Fragment based drug design (FBDD)	20-21
1.7.3.	Molecular docking	21-22
1.7.4.	Molecular dynamic simulations	22-23
1.8.	Research issues/gaps	23-24
1.9.	Research problem/problem formulation	24-25
1.10.	Aim and objectives	25
1.11.	Plan of work	25-26
CHAPTER 2	REVIEW OF LITERATURE	27-58
2.1.	Recent pyrimidine based anti-cancer agents	27-3
2.2.	Pyrimidine derivatives as MAPK pathway inhibitors	34-35
2.3.	Various small molecule heterocycles based ERK1/2 inhibitors	35
2.3.1.	Thiazolidine-2,4-dione-based inhibitors	35-37

2.3.2.	Tetrahydropyridopyrimidine-based inhibitors	37-38
2.3.3.	Coumarin-based inhibitors	38-39
2.3.4.	Benzhydroxamate ester-based inhibitors	39-40
2.3.5.	Pyridone-based inhibitors	40-42
2.3.6.	Amino pyrazole-based inhibitors	42-43
2.3.7.	Quinoline based inhibitors	44-47
2.3.8.	Guanidino based inhibitors	47-48
2.3.9.	Indole based inhibitors	48-49
2.3.10.	Pyrrolidine based inhibitors	49-50
2.3.11.	Indazole amide-based inhibitors	50-51
2.3.12.	Imidazolinone-based inhibitors	51-52
2.3.13.	Carbazole based inhibitors	52-54
2.3.14.	Pyrimidine-pyrrololactam based inhibitors	54
2.3.15.	Madecassic acid-based inhibitors	54-55
2.3.16.	Benzothiophene based inhibitors	55-56
2.4.	Pyrimidine based ERK inhibitors	56-58
CHAPTER 3	MATERIAL AND METHODS	59-81
3.1.	Molecular modeling	59
3.1.1.	Softwares	59-61
3.1.2.	Selection of ligand and protein	61
3.1.3.	Scaffold hopping	61-62
3.1.4.	Molecular docking	62-63
3.1.5.	Fragment based drug discovery	63-64
3.1.6.	Molecular dynamic simulations	64-65
3.1.7.	MM-GBSA calculation	65
3.1.8.	Density functional theory (DFT) analysis	65-66
3.1.9.	Improving the top hit: Library generation and screening of derivatives of the top hit	66-68
3.2.	Synthesis	68
3.2.1.	Chemistry	68
3.2.2.	General procedures for the synthesis of compounds pertaining to Formula-I	68-69

3.2.2.1.	Synthesis of (<i>E</i>)-1-(4-bromophenyl)-3-(4-substitutedphenyl)prop-2-en-1-one (3)	70
3.2.2.2.	Synthesis of 4-(4-bromophenyl)-6-(4-substitutedphenyl)pyrimidin-2-amine (5)	71
3.2.2.3.	Synthesis of final compounds pertaining to Formula-I (8a-8o)	72
3.2.3.	General procedures for the synthesis of compounds pertaining to Formula-II	73-74
3.2.3.1.	Synthesis of final compounds pertaining to Formula-II (10a-10o)	74-76
3.3.	Biological evaluation	76
3.3.1.	Enzymatic assay	76—77
3.3.1.1.	Procedure for enzymatic assay	77
3.3.1.2.	Analysis of data	78
3.3.2.	Anti-proliferative assay	78
3.3.2.1.	Cell lines under study	78-80
3.3.2.2.	Culturing of the cell lines	80
3.3.2.3.	Cytotoxicity assay (MTT)	80-81
3.3.2.4.	Procedure	81
CHAPTER 4	RESULTS AND DISCUSSION	82-165
4.1.	Molecular modeling analysis	82
4.1.1.	Virtual screening of ERK2 inhibitors <i>via</i> hybrid scaffold hopping–FBDD approach	82-98
4.1.2.	Improving binding affinity of the virtually screened hit (Ligand 8) <i>via</i> optimizing substituents (Formula-I)	99-109
4.1.3.	Exploring effect of ring size increase on binding affinity of hit (Ligand 8) derivatives (Formula-II)	109-117
4.2.	Results of synthesis	117-118
4.2.1.	List of synthesized compounds	118-120
4.2.2.	Characterization of compounds pertaining to Formula-I (8a-8o)	121-123
4.2.3.	Compound sheets	123

4.2.3.1.	3-(4-(4-bromophenyl)-6-(4-chlorophenyl)pyrimidin-2-yl)-2-(4-chlorophenyl)thiazolidin-4-one (8a)	123-124
4.2.3.2.	3-(4-(4-bromophenyl)-6-(4-chlorophenyl)pyrimidin-2-yl)-2-(2-chlorophenyl)thiazolidin-4-one (8b)	124
4.2.3.3.	3-(4-(4-bromophenyl)-6-(4-chlorophenyl)pyrimidin-2-yl)-2-(2-methoxyphenyl)thiazolidin-4-one (8c)	125
4.2.3.4.	3-(4-(4-bromophenyl)-6-(4-chlorophenyl)pyrimidin-2-yl)-2-(4-hydroxyphenyl)thiazolidin-4-one (8d)	126
4.2.3.5.	3-(4-(4-bromophenyl)-6-(4-chlorophenyl)pyrimidin-2-yl)-2-(2,5-dimethoxyphenyl)thiazolidin-4-one (8e)	127
4.2.3.6.	3-(4-(4-bromophenyl)-6-(4-chlorophenyl)pyrimidin-2-yl)-2-(2,4-dimethoxyphenyl)thiazolidin-4-one (8f)	128
4.2.3.7.	3-(4-(4-bromophenyl)-6-(4-chlorophenyl)pyrimidin-2-yl)-2-(4-nitrophenyl)thiazolidin-4-one (8g)	129
4.2.3.8.	3-(4-(4-bromophenyl)-6-(4-chlorophenyl)pyrimidin-2-yl)-2-phenylthiazolidin-4-one (8h)	130
4.2.3.9.	3-(4-(4-bromophenyl)-6-(4-chlorophenyl)pyrimidin-2-yl)-2-(2-nitrophenyl)thiazolidin-4-one (8i)	131
4.2.3.10.	3-(4-(4-bromophenyl)-6-(4-methoxyphenyl)pyrimidin-2-yl)-2-(4-methoxyphenyl)thiazolidin-4-one (8j)	132
4.2.3.11.	3-(4-(4-bromophenyl)-6-(4-methoxyphenyl)pyrimidin-2-yl)-2-(4-chlorophenyl)thiazolidin-4-one (8k)	133

4.2.3.12.	3-(4-(4-bromophenyl)-6-(4-methoxyphenyl)pyrimidin-2-yl)-2-(2-nitrophenyl)thiazolidin-4-one (8l)	134
4.2.3.13.	3-(4-(4-bromophenyl)-6-(4-methoxyphenyl)pyrimidin-2-yl)-2-(2-methoxyphenyl)thiazolidin-4-one (8m)	135
4.2.3.14.	3-(4-(4-bromophenyl)-6-(4-methoxyphenyl)pyrimidin-2-yl)-2-(2-chlorophenyl)thiazolidin-4-one (8n)	136
4.2.3.15.	3-(4-(4-bromophenyl)-6-(4-methoxyphenyl)pyrimidin-2-yl)-2-(4-hydroxyphenyl)thiazolidin-4-one (8o)	137
4.2.4.	Characterization of compounds pertaining to Formula-II (10a-10o)	137-140
4.2.5.	Compound sheets	140
4.2.5.1.	3-(4-(4-bromophenyl)-6-(4-chlorophenyl)pyrimidin-2-yl)-2-(4-chlorophenyl)-1,3-thiazinan-4-one (10a)	140-141
4.2.5.2.	3-(4-(4-bromophenyl)-6-(4-chlorophenyl)pyrimidin-2-yl)-2-(2-chlorophenyl)-1,3-thiazinan-4-one (10b)	141
4.2.5.3.	3-(4-(4-bromophenyl)-6-(4-chlorophenyl)pyrimidin-2-yl)-2-(2-methoxyphenyl)-1,3-thiazinan-4-one (10c)	142
4.2.5.4.	3-(4-(4-bromophenyl)-6-(4-chlorophenyl)pyrimidin-2-yl)-2-(4-hydroxyphenyl)-1,3-thiazinan-4-one (10d)	143
4.2.5.5.	3-(4-(4-bromophenyl)-6-(4-chlorophenyl)pyrimidin-2-yl)-2-(2,5-dimethoxyphenyl)-1,3-thiazinan-4-one (10e)	144
4.2.5.6.	3-(4-(4-bromophenyl)-6-(4-chlorophenyl)pyrimidin-2-yl)-2-(2,4-dimethoxyphenyl)-1,3-thiazinan-4-one (10f)	145

4.2.5.7.	3-(4-(4-bromophenyl)-6-(4-chlorophenyl)pyrimidin-2-yl)-2-(4-nitrophenyl)-1,3-thiazinan-4-one (10g)	146
4.2.5.8.	3-(4-(4-bromophenyl)-6-(4-chlorophenyl)pyrimidin-2-yl)-2-phenyl-1,3-thiazinan-4-one (10h)	147
4.2.5.9.	3-(4-(4-bromophenyl)-6-(4-chlorophenyl)pyrimidin-2-yl)-2-(2-nitrophenyl)-1,3-thiazinan-4-one (10i)	147-148
4.2.5.10.	3-(4-(4-bromophenyl)-6-(4-methoxyphenyl)pyrimidin-2-yl)-2-(4-methoxyphenyl)-1,3-thiazinan-4-one (10j)	148-149
4.2.5.11.	3-(4-(4-bromophenyl)-6-(4-methoxyphenyl)pyrimidin-2-yl)-2-(4-chlorophenyl)-1,3-thiazinan-4-one (10k)	149-150
4.2.5.12.	3-(4-(4-bromophenyl)-6-(4-methoxyphenyl)pyrimidin-2-yl)-2-(2-nitrophenyl)-1,3-thiazinan-4-one (10l)	150-151
4.2.5.13.	3-(4-(4-bromophenyl)-6-(4-methoxyphenyl)pyrimidin-2-yl)-2-(2-methoxyphenyl)-1,3-thiazinan-4-one (10m)	151-152
4.2.5.14.	3-(4-(4-bromophenyl)-6-(4-methoxyphenyl)pyrimidin-2-yl)-2-(2-chlorophenyl)-1,3-thiazinan-4-one (10n)	152-153
4.2.5.15.	3-(4-(4-bromophenyl)-6-(4-methoxyphenyl)pyrimidin-2-yl)-2-(4-hydroxyphenyl)-1,3-thiazinan-4-one (10o)	153-154
4.3.	Biological evaluation	154
4.3.1.	Enzymatic activity	154-157
4.3.2.	Anti-cancer activity	157-161
4.3.3.	Normal cell toxicity	161-162
4.4.	Structural activity relationship study (SAR)	162
4.4.1.	For Formula I compounds (thiazolidinone-	162-164

	pyrimidine derivatives)	
4.4.2.	For Formula II compounds (thiazinanone-pyrimidine derivatives)	14-165
CHAPTER 5	SUMMARY AND CONCLUSION	166-170
	REFERENCES	171-190
	APPENDIX	191-223